Abbott
This article was originally published in The Gray Sheet
Executive Summary
Plans first quarter 1994 worldwide launch of its AxSym random, continuous and immediate access immunoassay analyzer and Maestro data management system, which allows "the integration of up to eight analyzers." Abbott announced development of AxSym in November 1992 ("The Gray Sheet" Nov. 16, 1992, p. 11). The two devices were previewed at an American Association for Clinical Chemistry meeting in New York. Shipments are to begin following FDA clearance of assays for the analyzer, which was okayed for marketing in 1992. The AxSym will list for about $124,000, and the Maestro will carry a price of "just over $38,000".